Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Dose Selection for ME1100, an Arbekacin Inhalation Solution-Reference-Cited by-同舟云学术

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Dose Selection for ME1100, an Arbekacin Inhalation Solution

Published:2020-09-21 Issue:10 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Bhavnani Sujata M.¹^ORCID,Hammel Jeffrey P.¹,Lakota Elizabeth A.¹,Safir M. Courtney¹,VanScoy Brian D.¹^ORCID,Nagira Yu²,Rubino Christopher M.¹,Sato Nobuo²,Koresawa Tomokazu²,Kondo Kenichiro²,Ambrose Paul G.¹

Affiliation:

1. Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA

2. Meiji Seika Pharma Co., Ltd., Tokyo, Japan

Abstract

ME1100 (arbekacin inhalation solution) is an inhaled aminoglycoside that is being developed to treat patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP, respectively). Pharmacokinetic-pharmacodynamic (PK-PD) target attainment analyses were undertaken to evaluate ME1100 regimens for the treatment of patients with HABP/VABP. The data used included a population pharmacokinetic (PPK) 4-compartment model with 1st-order elimination, nonclinical PK-PD targets from one-compartment in vitro and/or in vivo infection models, and in vitro surveillance data.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02367-19

Reference47 articles.

1. Is ventilator-associated pneumonia an independent risk factor for death?;Bregeon F;Anesthesiology,2001

2. The occurrence of ventilator-associated pneumonia in a community hospital: risk factors and clinical outcomes;Ibrahim EH;Chest,2001

3. Epidemiology and Outcomes of Ventilator-Associated Pneumonia in a Large US Database

4. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review;Safdar N;Crit Care Med,2005

5. Attributable mortality of ventilator-associated pneumonia: respective impact of main characteristics at ICU admission and VAP onset using conditional logistic regression and multi-state models;Nguile-Makao N;Intensive Care Med,2010

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of MRSA Infection: Where are We?;Current Medicinal Chemistry;2024-08

2. Arbekacin-Loaded Inhalable Nanocomposite Particles Specific to <i>Pseudomonas aeruginosa</i> Prepared Using a Two-Solution Mixing-Type Spray Nozzle;Biological and Pharmaceutical Bulletin;2023-02-01